The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Johnathan Whetstine to lead Cancer Epigenetics Program at Fox Chase

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Johnathan Whetstine was named program leader of the Cancer Epigenetics Program at Fox Chase Cancer Center.

Whetstine comes to Fox Chase from Massachusetts General Hospital Cancer Center and Harvard Medical School, where he served as vice chair of the Epigenetics Program. He also held appointments as associate geneticist and associate professor in the department of medicine.

Whetstine’s work has focused on understanding tumor heterogeneity and drug response. He holds the scholar award from the Leukemia & Lymphoma Society and an NIH R01 grant, as well as funding from the American Lung Association, Alex Lemonade Stand Foundation and AstraZeneca.

The new Cancer Epigenetics Program Whetstine will lead has basic, translational, and clinical research components.

Whetstine will begin his work at Fox Chase on Dec. 1.

Table of Contents

YOU MAY BE INTERESTED IN

ClinicalTrials & Tribulations

The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe

Those of us who have devoted our careers to treating recalcitrant cancers know the heartbreak of walking alongside an individual facing an advanced diagnosis. We not only shoulder the clinical responsibility, but also the emotional weight that accompanies every step of that journey as each patient’s story becomes connected to our own.
By W. Kimryn Rathmell

At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer

If you believe in the miraculous healing power of ivermectin, hydroxychloroquine, and the harm from vaccination for HPV and COVID-19, you’ve got a powerful friend in Sen. Ron Johnson (R-WI), chair of the Permanent Subcommittee on Investigations of the Senate Committee on Homeland Security and Governmental Affairs.
By Sara Willa Ernst, Claire Marie Porter and Paul Goldberg

Eric Small, ASCO’s immediate past president, speaks on the toll of toxicity—financial, emotional, physical—in cancer
“Discovery alone is not enough. It’s about what becomes of what we discover. It’s about translation.”

In a poignant keynote punctuated with anecdotes about grief, American Society of Clinical Oncology’s immediate past president Eric Small emphasized that the annual conference is not just about scientific discovery, but about a responsibility to translate discoveries into better outcomes for cancer patients globally. 
By Claire Marie Porter
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account